These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 36894588)

  • 21. Triple-negative breast cancer in Hispanic patients: high prevalence, poor prognosis, and association with menopausal status, body mass index, and parity.
    Lara-Medina F; Pérez-Sánchez V; Saavedra-Pérez D; Blake-Cerda M; Arce C; Motola-Kuba D; Villarreal-Garza C; González-Angulo AM; Bargalló E; Aguilar JL; Mohar A; Arrieta Ó
    Cancer; 2011 Aug; 117(16):3658-69. PubMed ID: 21387260
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumour-infiltrating lymphocytes as a prognostic and tamoxifen predictive marker in premenopausal breast cancer: data from a randomised trial with long-term follow-up.
    Lundgren C; Bendahl PO; Ekholm M; Fernö M; Forsare C; Krüger U; Nordenskjöld B; Stål O; Rydén L
    Breast Cancer Res; 2020 Dec; 22(1):140. PubMed ID: 33357231
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.
    Turkoz FP; Solak M; Petekkaya I; Keskin O; Kertmen N; Sarici F; Arik Z; Babacan T; Ozisik Y; Altundag K
    J BUON; 2013; 18(2):335-41. PubMed ID: 23818343
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicopathological characteristics of triple negative breast cancer at a tertiary care hospital in India.
    Dogra A; Doval DC; Sardana M; Chedi SK; Mehta A
    Asian Pac J Cancer Prev; 2014; 15(24):10577-83. PubMed ID: 25605142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors - An analysis of 2765 patients from neoadjuvant clinical trials.
    Villegas SL; Nekljudova V; Pfarr N; Engel J; Untch M; Schrodi S; Holms F; Ulmer HU; Fasching PA; Weber KE; Albig C; Heinrichs C; Marmé F; Hartmann A; Hanusch C; Schmitt WD; Huober J; Lederer B; van Mackelenbergh M; Tesch H; Jackisch C; Rezai M; Sinn P; Sinn BV; Hackmann J; Kiechle M; Schneeweiss A; Weichert W; Denkert C; Loibl S
    Eur J Cancer; 2021 May; 148():159-170. PubMed ID: 33743484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
    Hamy AS; Darrigues L; Laas E; De Croze D; Topciu L; Lam GT; Evrevin C; Rozette S; Laot L; Lerebours F; Pierga JY; Osdoit M; Faron M; Feron JG; Laé M; Reyal F
    PLoS One; 2020; 15(6):e0234191. PubMed ID: 32579551
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Time Since Last Childbirth on Survival of Women with Premenopausal and Postmenopausal Breast Cancers.
    Balakrishnan N; Teo SH; Sinnadurai S; Bhoo Pathy NT; See MH; Taib NA; Yip CH; Bhoo Pathy N
    World J Surg; 2017 Nov; 41(11):2735-2745. PubMed ID: 28653143
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic and demographic evaluation of triple- negative breast cancer patients among a turkish patient population: a single center experience.
    Somali I; Ustaoglu BY; Tarhan MO; Yigit SC; Demir L; Ellidokuz H; Erten C; Alacacioglu A
    Asian Pac J Cancer Prev; 2013; 14(10):6013-7. PubMed ID: 24289617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Outcomes in patients with small node-negative invasive breast cancer.
    Bao J; Donovan C; Amersi F; Zhang X; Giuliano AE; Chung A
    Breast J; 2019 Jul; 25(4):638-643. PubMed ID: 31079425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of HER2-zero and HER2-low in terms of clinicopathological factors and survival in early-stage breast cancer: A systematic review and meta-analysis.
    Ergun Y; Ucar G; Akagunduz B
    Cancer Treat Rev; 2023 Apr; 115():102538. PubMed ID: 36898351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relationship of established risk factors with breast cancer subtypes.
    McCarthy AM; Friebel-Klingner T; Ehsan S; He W; Welch M; Chen J; Kontos D; Domchek SM; Conant EF; Semine A; Hughes K; Bardia A; Lehman C; Armstrong K
    Cancer Med; 2021 Sep; 10(18):6456-6467. PubMed ID: 34464510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pooled case-only analysis of obesity and breast cancer subtype among Black women in the southeastern United States.
    Moore J; Pal T; Beeghly-Fadiel A; Fadden MK; Munro HM; Dujon SA; Reid S; Tezak A; Blasingame M; Ware J; Blot WJ; Shu XO; Zheng W; Sanderson M; Lipworth L
    Cancer Causes Control; 2022 Apr; 33(4):515-524. PubMed ID: 35088206
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes - an observational cohort study in Sweden.
    Lindman H; Wiklund F; Andersen KK
    BMC Cancer; 2022 Sep; 22(1):1006. PubMed ID: 36138404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triple Negative Breast Cancer: An Analysis of the Subtypes and the Effects of Menopausal Status on Invasive Breast Cancer.
    Nishimura R; Osako T; Okumura Y; Nakano M; Otsuka H; Fujisue M; Arima N
    J Clin Med; 2022 Apr; 11(9):. PubMed ID: 35566456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accuracy of morphologic change measurements by ultrasound in predicting pathological response to neoadjuvant chemotherapy in triple-negative and HER2-positive breast cancer.
    Ochi T; Tsunoda H; Matsuda N; Nozaki F; Suzuki K; Takei H; Yamauchi H
    Breast Cancer; 2021 Jul; 28(4):838-847. PubMed ID: 33560514
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment and survival of patients diagnosed with high-risk HR+/HER2- breast cancer in the Netherlands: a population-based retrospective cohort study.
    Lammers SWM; Meegdes M; Vriens IJH; Voogd AC; de Munck L; van Nijnatten TJA; Keymeulen KBMI; Tjan-Heijnen VCG; Geurts SME
    ESMO Open; 2024 May; 9(5):103008. PubMed ID: 38677006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2-positive is an independent indicator for predicting pathological complete response to neoadjuvant therapy and Ki67-changed after neoadjuvant chemotherapy predicts favorable prognosis in Chinese women with locally advanced breast cancer.
    Fang Y; Zhang Q; Wu Y; Wu J
    Medicine (Baltimore); 2024 Feb; 103(6):e37170. PubMed ID: 38335419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patients.
    Bae SY; La Choi Y; Kim S; Kim M; Kim J; Jung SP; Choi MY; Lee SK; Kil WH; Lee JE; Nam SJ
    Breast Cancer Res Treat; 2013 Jun; 139(3):741-50. PubMed ID: 23722313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Retrospective analysis of clinicopathological characteristics and family history data of early-onset breast cancer: a single-institutional study of Hungarian patients.
    Madaras L; Baranyák Z; Kulka J; Szász AM; Kovács A; Lan PH; Székely B; Dank M; Nagy T; Kiss O; Harsányi L; Barbai T; Kenessey I; Tőkés AM
    Pathol Oncol Res; 2013 Oct; 19(4):723-9. PubMed ID: 23709114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.